Evalation of the Impact of the Implementation of a Specialty Pharmacy Program in the Treatment of Hepatitis C (HCV)

Authors

Trisha V. Pedone, Advocate Aurora HealthFollow
Erika Aldag, Advocate Aurora HealthFollow
Rachel Pedersen, Advocate Aurora HealthFollow
Siddesh Besur, Advocate Aurora HealthFollow
Kamran Safdar
Ajay Sahajpal, Advocate Aurora HealthFollow

Recommended Citation

Pedone T, Aldag E, Pedersen R, Besur S, Safdar K, Sahajpal A. Evaluation of the Impact of the Implementation of a Specialty Pharmacy Program in the Treatment of Hepatitis C (HCV). Poster presented at: Aurora Scientific Day; May 25, 2016; Milwaukee, WI.

Affiliations

Department of Pharmacy, St. Luke's Medical Center, Abdominal Transplant

Presentation Notes

Poster presented at: Aurora Scientific Day; May 25, 2016; Milwaukee, WI.

Abstract

Conclusion: SVR (sustained virologic response) rates are comparable to clinical trials in this real-life clinical setting using a specialty pharmacy program. Those with HCV Genotype 1A had lower SVR rates post-medication completion, though it did not reach statistical significance. There was no difference in SVR rates between previously treated and treatment-naive patients.

Document Type

Poster